Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hepatic encephalopathy and ascites

R Jalan1, P C Hayes

  • 1Department of Medicine, Royal Infirmary of Edinburgh, UK. rjalan@srv2.med.ed.ac.uk

Lancet (London, England)
|November 14, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Volatomics for Diagnosis and Risk Stratification of MASLD: A Proof-Of-Concept Study.

Alimentary pharmacology & therapeutics·2025
Same author

Multimodal decoding of human liver regeneration.

Nature·2024
Same author

Increased case-finding and uptake of direct-acting antiviral treatment essential for micro-elimination of hepatitis C among people living with HIV: a national record linkage study.

HIV medicine·2020
Same author

Letter to the editor: 'Human based systems: Mechanistic NASH modelling just around the corner?'

Pharmacological research·2018
Same author

Index serum hyaluronic acid independently and accurately predicts mortality in patients with liver disease.

Alimentary pharmacology & therapeutics·2018
Same author

Impact of previous hepatitis B infection on the clinical outcomes from chronic hepatitis C? A population-level analysis.

Journal of viral hepatitis·2018
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
See all related articles

Cirrhosis causes sodium and water retention due to kidney defects and hormonal imbalances. Research should focus on intrarenal factors to improve kidney function and treat portal hypertension effectively.

Area of Science:

  • Nephrology
  • Hepatology
  • Cardiovascular Physiology

Background:

  • Cirrhosis leads to sodium and water retention via renal tubular defects, exacerbated by declining liver function and hyperaldosteronism.
  • Progressive liver disease and portal hypertension impair renal blood flow through the hepatorenal reflex, necessitating compensatory vasoactive hormonal systems.
  • Peripheral vasodilatation in cirrhosis triggers intrarenal vasoconstriction, complicating renal perfusion maintenance.

Purpose of the Study:

  • To elucidate the mechanisms of renal dysfunction in cirrhosis.
  • To identify targets for improving renal blood flow and managing portal hypertension.
  • To guide the development of ideal therapeutic agents for portal hypertension.

Main Methods:

  • Review of physiological mechanisms underlying renal abnormalities in cirrhosis.

Related Experiment Videos

  • Analysis of the roles of systemic and intrarenal vasoactive factors.
  • Discussion of the implications for therapeutic interventions.

    • Main Results:

    • Renal tubular defects and hyperaldosteronism are primary drivers of fluid retention in cirrhosis.
    • The hepatorenal reflex and compensatory vasoactive systems attempt to maintain renal perfusion despite declining blood flow.
    • Intrarenal vasoconstriction intensifies with peripheral vasodilatation, posing risks to renal function.

    Conclusions:

    • Systemic vasoactive factors are largely compensatory; interventions carry risks of circulatory collapse.
    • Future research should prioritize investigating intrarenal factors influencing renal perfusion.
    • The ideal treatment for portal hypertension should lower portal pressure, enhance renal blood flow, and minimally affect arterial pressure.